Cellmat Therapeutics Submits Objection to Delisting Notice

[Asia Economy Reporter Kim Young-won] Cellmat Therapeutics announced on the 8th that it has submitted an objection to the delisting. Cellmat Therapeutics also received a refusal of audit opinion from the auditor on its financial statements for the 2020 fiscal year.

The company stated, "The Korea Exchange will hold a Securities Market Listing Disclosure Committee meeting to conduct a combined review of the delisting reasons related to the audit opinions for the 2020 and 2021 fiscal years and will decide on the delisting status of Cellmat Therapeutics."